Alzheimer's & Other Dementias

Latest news

While everyone agrees that amyloid-beta protein is part of the problem, not everyone agrees that amyloid plaques are the cause (or one of them) of Alzheimer’s. A new study provides convincing evidence that floating clumps called oligomers or ADDLs are the real problem.

While everyone agrees that amyloid-beta protein is part of the problem, not everyone agrees that amyloid plaques are the cause (or one of them) of Alzheimer’s. Other forms of amyloid-beta have been pointed to, including floating clumps called oligomers or ADDLs.

Another study using a different strain of genetically engineered mice has confirmed the finding that the transplant drug rapamycin prevented cognitive impairment.

A few months ago, I reported on an exciting finding that

The American Academy of Neurology has updated its guidelines on when people with dementia should stop driving. The guidelines support caregivers’ instincts, but not use of the patient’s own self-rating.

The American Academy of Neurology has updated its guidelines on when people with dementia should stop driving.

Another gene has been identified that appears to increase risk of Alzheimer’s. The gene is involved in influencing the body's levels of homocysteine (high levels are known to be a strong risk factor), and have also been implicated in coronary artery disease.

Another gene has been identified that appears to increase risk of Alzheimer’s. The gene, MTHFD1L, is located on chromosome six.

The Phase II clinical trial of a treatment using naturally occurring antibodies has been successful in slowing (and in some cases preventing) the progression of the disease in patients with mild-to-moderate Alzheimer's. A much larger trial is now being carried out.

The Phase II clinical trial of a treatment using naturally occurring antibodies (IGIV) has achieved significantly lower rates of ventricular enlargement (6.7% vs 12.7% per year) and less whole-brain atrophy (1.6% vs 2.2% per year) than control subjects who initially received placebo.

Previous research has found that unexplained weight loss is an early sign of Alzheimer's. Now a new study has revealed that it is not the overall weight or fat levels that are important, but the loss of lean mass (weight of an individual's bones, muscles and organs without body fat).

Previous research has found that unexplained weight loss is an early sign of Alzheimer's.

Alzheimer's mice significantly benefited from taking a drug used to treat hypertension.

Two mouse experiments have found that the drug carvedilol, prescribed for the treatment of hypertension, significantly improved synaptic transmission in Alzhei

A study finds poor learning plus depression or slow processing speed predicts the development of amnestic mild cognitive impairment for seniors.

Amnestic mild cognitive impairment often leads to Alzheimer's disease, but what predicts aMCI?

A pilot study found daily apple juice improved behavioral and psychotic symptoms in those with moderate-to-severe Alzheimer’s.

A pilot study involving 21 institutionalized individuals with moderate-to-severe Alzheimer’s found that, although drinking two 4-oz glasses of apple juice daily for a month produced no change in the Dementia Rating Scale or in the Activities of Daily Living measure, there was a significant (27%)

A pilot study found two weeks of daily repetitive transcranial magnetic stimulation to the prefrontal lobes improved speech comprehension in those with moderate Alzheimer's.

A pilot study involving 10 patients with moderate Alzheimer's disease, of whom half were randomly assigned to the treatment, has found that two weeks of receiving daily (25 minute) periods of repetitive transcranial magnetic stimulation to the prefrontal

Pages